谈及近期股债双双震荡背后的原因，他分析称，临近年底，股票行情短期存在回调压力。债市方面，近 期的震荡波折主要受到一些机构行为和资管机构负债端波动的影响。 展望明年，看好反内卷、医药、低估值传统行业、科技等四大方向的投资机会。反内卷板块中，关注光 伏、锂电、养殖、快递等；医药板块中，关注一些估值位于底部的细分领域，如耗材、原料药、医药流 通等；低估值传统行业板块中，关注零售、轻工、纺织服装等；科技板块关注非高位品种，如计算机、 电子(偏软件)等。债市方面，投资策略将以短久期、持有获取票息为主。 中证报中证网讯(记者张韵)12月11日晚间，大成元瑞诚利拟任基金经理苏秉毅在做客中国证券报"中证 点金汇"直播间时表示，长期来看，股债市场往往存在跷跷板效应，但短期看，受多种因素的影响，这 种效应可能阶段性失灵。 ...

Summary of Key Points from Conference Call Records Industry Overview - The conference call discusses the **innovative drug and pharmaceutical industry** in China, highlighting the recovery of PS and PB ratios in Hong Kong's creative sales companies, although they have not yet reached historical highs, indicating a period of recovery [1][2]. Core Insights and Arguments - **Global Competitiveness of Chinese Innovative Drugs**: China possesses advantages in population, domestic demand, manufacturing, supply chain, and rapidly improving innovation capabilities, which are driving Chinese assets to go global. High-quality early-stage products from China are in significant demand in the U.S. market, with leading companies gradually increasing their performance [1][3]. - **Valuation Trends**: The innovative drug sector's valuation is expected to first recover to previous PS levels and then potentially break new highs as more products are launched and clinical data is disclosed. The number of products is projected to increase, which will enhance company valuations [1][4]. - **Performance of Kangfang Biotech**: Kangfang Biotech's data presented at WCLC showed a p-value of 0.000332 and an HR value of 0.78, indicating significant improvement, especially in brain metastasis patients, which is a rare and meaningful finding [1][5]. - **International Conference Participation**: In 2025, over 70 Chinese studies were showcased at ASCO, with ongoing presentations at international conferences like WCLC and ESMO, indicating China's growing international influence in innovative drug development [1][6][8]. Additional Important Content - **Diverse Treatment Areas**: The innovative drug trend is not limited to oncology but also includes immunology, with upcoming data releases at various international conferences, showcasing significant progress in multiple therapeutic areas [1][8]. - **Future Growth Expectations**: The Chinese innovative drug industry is anticipated to continue significant growth in the coming years, with more new data and products expected as operational logic is refined. The collaboration models are diversifying, enhancing China's global pricing power and influence [1][9]. - **Catalysts for Market Impact**: The second half of 2025 is expected to bring several important catalysts for the Chinese innovative drug market, including potential approvals for new products from leading companies like Heng Rui and developments from companies like Innovent Biologics and BeiGene [1][10][11]. - **Heng Rui Pharmaceutical's Performance**: As a leading company, Heng Rui's performance in the first half of 2025 was outstanding, with a significant increase in the number of products contributing to sales, reflecting its strong position in global transactions [1][12]. - **Innovent Biologics' Growth**: Innovent Biologics reported significant revenue growth of 5.95 billion, a 50.6% year-on-year increase, indicating improved operational efficiency [1][13]. - **Kangfang Biotech's Platform Value**: Kangfang Biotech demonstrated strong performance with a 49.2% growth in product revenue, showcasing its platform's value and potential for new dual and multi-antibody assets [1][14]. - **Bai Jie Shen Zhou's Financial Performance**: Bai Jie Shen Zhou reported a 17.5% quarter-on-quarter revenue increase, exceeding expectations, with new data updates expected in the second half of the year [1][16]. Conclusion - The innovative drug industry in China is on a recovery trajectory, with strong growth potential driven by competitive advantages, increasing product launches, and expanding international presence. The upcoming catalysts and ongoing developments in various companies are expected to further enhance the industry's outlook.

Performance Forecast - The company expects a net loss attributable to shareholders of 200 million to 400 million yuan for the first half of 2025, compared to a profit of 973.64 million yuan in the same period last year [1][2] - The net profit after deducting non-recurring gains and losses is projected to be a loss of 100 million to 200 million yuan, down from a profit of 623.52 million yuan year-on-year [1][2] - Basic earnings per share are expected to be a loss of 0.1406 to 0.2813 yuan, compared to earnings of 0.6891 yuan per share in the previous year [1][2] Business Segments Printer Business - The sales volume of printers in the Xinchuang market has significantly increased, with a year-on-year growth of approximately 65% in the first half of the year [1] - The sales volume of A3 copiers increased by about 115% year-on-year, with a quarter-on-quarter growth of approximately 30% in the second quarter [1] Integrated Circuit Business - Revenue from non-consumable chips reached approximately 254 million yuan, a year-on-year increase of about 52% [2] - The total shipment of chips was 168 million units, with a quarter-on-quarter growth of about 34% [2] General Consumables Business - Revenue from general consumables decreased by approximately 61% year-on-year, while total sales volume remained flat [2] Asset Disposal Impact - The company completed the major asset sale on July 1, 2025, which has significantly impacted the net profit and net profit after deducting non-recurring gains and losses [2] - The final confirmation of the transaction amount may be adjusted, potentially affecting the performance forecast data [2]